title: When and how to use maraviroc in HIV-infected patients.
authors.forename: Vincent
authors.initials: V
authors.lastname: Soriano
authors.forename: Carlo-Federico
authors.initials: CF
authors.lastname: Perno
authors.forename: Rolf
authors.initials: R
authors.lastname: Kaiser
authors.forename: Vincent
authors.initials: V
authors.lastname: Calvez
authors.forename: Jose M
authors.initials: JM
authors.lastname: Gatell
authors.forename: Giovanni
authors.initials: G
authors.lastname: di Perri
authors.forename: Deenan
authors.initials: D
authors.lastname: Pillay
authors.forename: Juergen
authors.initials: J
authors.lastname: Rockstroh
authors.forename: Anna María
authors.initials: AM
authors.lastname: Geretti
mesh_terms: D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D024882:Drug Resistance, Viral / Q000502:physiology; D023581:HIV Fusion Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D000077592:Maraviroc; D014230:Triazoles / Q000493:pharmacokinetics / Q000627:therapeutic use*; D056189:Viral Tropism / Q000502:physiology*
chemical_list: D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D014230:Triazoles; D000077592:Maraviroc